Achim Schlapbach

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Harnessing Glutamine-117 Plasticity toward Structure-Based Identification of Triazole IL-17 Inhibitors.

Harnessing Glutamine-117 Plasticity toward Structure-Based Identification of Triazole IL-17 Inhibitors.

Journal: Journal of medicinal chemistry

Published: December 08, 2025

Thiazole-Based IL-17 Inhibitors Discovered by Scaffold Morphing.

Thiazole-Based IL-17 Inhibitors Discovered by Scaffold Morphing.

Journal: ChemMedChem

Published: October 25, 2024

Discovery and In Vivo Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors.

Discovery and In Vivo Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors.

Journal: Journal of medicinal chemistry

Published: September 14, 2024

Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.

Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.

Journal: Biochemical and biophysical research communications

Published: January 15, 2021

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.

Journal: Journal of medicinal chemistry

Published: November 30, 2020

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.

Journal: Journal of medicinal chemistry

Published: November 20, 2020

Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.

Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.

Journal: Journal of medicinal chemistry

Published: August 29, 2020

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.

Journal: Frontiers in immunology

Published: January 17, 2020

Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.

Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2019

Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.

Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.

Journal: ChemMedChem

Published: March 27, 2019

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: June 28, 2018

Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

Journal: ACS medicinal chemistry letters

Published: February 28, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026